-
-
-
-
-
-
-
GlaxoSmithKline (GSK) Reports Q1 EPS of GBP0.47
-
-
-
-
-
-
-
Morgan Stanley Reiterates Underweight Rating on GlaxoSmithKline (GSK:LN) (GSK): "risk/reward skewed to downside"
-
-
-
-
-
-
-
Guggenheim Downgrades Rapt Therapeutics (RAPT) to Neutral
-
-
-
-
-
-
-
GSK receives Japan approval for asthma and nasal polyp treatment
-
-
-
-
-
-
-
GSK terminates collaboration agreement with IDEAYA Biosciences
-
-
-
-
-
-
-
FDA approves GSK's Blenrep for relapsed multiple myeloma treatment
-
-
-
-
-
-
-
GlaxoSmithKline (GSK) Misses Q2 EPS by 71c
-
413,534 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

